DiaSorin (OTCMKTS:DSRLF) Shares Gap Down – Here’s Why

Posted by Stanley Muller on Jul 22nd, 2026

DiaSorin S.p.A. (OTCMKTS:DSRLF – Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $80.40, but opened at $77.58. DiaSorin shares last traded at $77.58, with a volume of 20 shares changing hands.

Analyst Upgrades and Downgrades

DSRLF has been the topic of a number of recent analyst reports. BNP Paribas Exane lowered DiaSorin from a “neutral” rating to an “underperform” rating in a research note on Tuesday, July 7th. Deutsche Bank Aktiengesellschaft lowered shares of DiaSorin from a “hold” rating to a “sell” rating in a research report on Wednesday, June 17th. Zacks Research upgraded DiaSorin to a “hold” rating in a research note on Tuesday, May 12th. Piper Sandler started coverage on shares of DiaSorin in a research note on Thursday, June 11th. They issued a “neutral” rating for the company. Finally, UBS Group downgraded shares of DiaSorin from a “buy” rating to a “neutral” rating in a research report on Thursday, April 9th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, DiaSorin presently has an average rating of “Hold”.

View Our Latest Stock Analysis on DiaSorin

DiaSorin Stock Up 3.1%

The company’s fifty day simple moving average is $76.55 and its two-hundred day simple moving average is $76.42.

DiaSorin Company Profile

(Get Free Report)

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.